Scientific article
Open access

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer

Published inClinical medicine insights. Oncology, vol. 17, 11795549231152948
Publication date2023
First online date2023-02-14

Lung cancer remains the leading cause of cancer-related death with an incidence that continues to increase in both sexes and all ages. However, 80% to 90% of lung cancers are non-small cell lung cancer (NSCLC) and the remaining 10% to 20% are small cell lung cancer. Adenocarcinoma is the most common histologic subtype of lung cancer worldwide. More frequently, lung cancer diagnosis is made in advanced stages. Stage III NSCLC refers to locoregionally advanced disease without metastases and represents about 30% NSCLC cases. Despite the absence of metastases at diagnosis, the outcome is generally poor. Stage III comprises a heterogeneous group and optimal management requires the input of a multidisciplinary team. All modalities of oncologic treatment are involved: surgery, chemotherapy, radiotherapy, and more recently, immunotherapy and targeted therapy. We will discuss the different therapeutic options in stage III NSCLC, both in operable and inoperable scenarios, and the role of immunotherapy and targeted therapy.

  • Heterogeneity
  • Multidisciplinary team
  • Non-small cell lung cancer
Citation (ISO format)
BAUDOUX, Nathalie, FRIEDLAENDER, Alex, ADDEO, Alfredo. Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer. In: Clinical medicine insights. Oncology, 2023, vol. 17, p. 11795549231152948. doi: 10.1177/11795549231152948
Main files (1)
Article (Published version)
ISSN of the journal1179-5549

Technical informations

Creation07/31/2023 12:44:54 PM
First validation10/05/2023 9:40:06 AM
Update time10/05/2023 9:40:06 AM
Status update10/05/2023 9:40:06 AM
Last indexation02/01/2024 10:46:23 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack